The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

The presentation will be available on Azitra’s website at https://ir.azitrainc.com/news-events/presentations.

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

Astrazeneca Pharma India said that it has received permission from Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab solutions (IMFINZI) in India.

诺和诺德因减肥药价格问题面临美参议院质询。9月23日，美国参议院网站显示，美参议院将于当地时间9月24日举行听证会，审查诺和诺德是否为糖尿病和肥胖患者提供价格过高的司美格鲁肽产品Ozempic和Wegovy。强生EGFR/c-MET双抗再获批准。9月20日，强生宣布，FDA已批准其EGFR/c-MET双抗Rybrevant与标准化疗，联合治疗在接受EGF ...

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

Discover AstraZeneca's groundbreaking patent for dual-target antibody molecules aimed at EGFR and c-Met, paving the way for innovative cancer therapies.

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...